Bupropion: new therapy for depression.
Level V
Where this comes from
- Record sourced from PubMed, PMID 2112333.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bupropion is one of the most recently approved antidepressant drugs. The drug differs in chemical structure from the tricyclic antidepressants. It mechanism of action is unknown. Bupropion weakly blocks dopamine uptake, but this property does not seem to account for the antidepressant effects. In clinical trials, bupropion has shown satisfactory antidepressant action compared with placebo. Because long-term effects are not well established, bupropion should be discontinued after several months of therapy.